SCHEMBL5682285

SCHEMBL5682285

Cc1ccccc1C(=O)OC[C@H]1O[C@@H](OC(=O)c2ccccc2)[C@](C)(OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 3/20 0.38
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RAB9A P51151 1/20 0.36
GAPDH P04406 1/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 2/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
BCHE P06276 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5680406 0.93 ADRB2 (0.37) ALDH1A1NPC1ADRB2ADRB1ADRB3
SCHEMBL721635 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL14571165 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL14037391 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL19276651 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL14853799 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL882168 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL21418908 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL21418911 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH
SCHEMBL13941468 0.90 ALDH1A1 (0.49) ALDH1A1NPC1MEN1KMT2AGAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US claimed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US claimed
EP-1631573-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO SpA (IT) 2006-03-08 EP disclosed
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US disclosed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 WO disclosed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158059-A1 Process for the preparation of ribofuranose derivatives RNGTT, RPIA, MRM1 ALDH1A1 960/4885NPC1 2950/4885ADRB2 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.